Maurizio Civelli Selected Research

Type 4 Cyclic Nucleotide Phosphodiesterases

10/2022	The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation.
4/2022	The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.
1/2021	Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease.
1/2021	The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs.
1/2019	The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
12/2017	Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
3/2015	CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maurizio Civelli Research Topics

Disease

19	Chronic Obstructive Pulmonary Disease (COPD) 10/2022 - 06/2006
11	Asthma (Bronchial Asthma) 01/2021 - 02/2005
10	Pneumonia (Pneumonitis) 01/2022 - 11/2007
9	Neoplasms (Cancer) 01/2020 - 10/2002
8	Cardiotoxicity 01/2020 - 08/2005
5	Inflammation (Inflammations) 04/2022 - 05/2007
5	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022 - 04/2007
5	Heart Failure 01/2016 - 08/2005
3	Lung Diseases (Lung Disease) 04/2022 - 03/2015
3	Nausea 01/2021 - 03/2015
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 01/2019
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 06/2004
3	Left Ventricular Dysfunction 01/2018 - 06/2004
3	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2018 - 01/2017
3	Lung Neoplasms (Lung Cancer) 08/2016 - 03/2007
3	Infections 01/2016 - 01/2014
2	Diarrhea 01/2021 - 01/2020
2	Fibrosis (Cirrhosis) 10/2020 - 01/2020
2	Airway Remodeling 09/2017 - 10/2015
2	Atrial Fibrillation 08/2016 - 03/2007
2	Neurogenic Inflammation 12/2010 - 07/2008
2	Breast Neoplasms (Breast Cancer) 09/2010 - 07/2006
2	Body Weight (Weight, Body) 12/2005 - 03/2002
1	Newborn Respiratory Distress Syndrome 01/2022
1	Weight Loss (Weight Reduction) 01/2021
1	Abdominal Pain (Pain, Abdominal) 01/2021
1	Atopic Dermatitis (Atopic Eczema) 01/2021
1	COVID-19 01/2021
1	Chronic Bronchitis 01/2021
1	Disease Progression 10/2020
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 10/2020
1	Human Influenza (Influenza) 01/2020
1	Psoriatic Arthritis 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Headache (Headaches) 01/2020
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020
1	Bronchopulmonary Dysplasia 12/2017
1	Hypertrophy 10/2015

Drug/Important Bio-Agent (IBA)

13	Phosphodiesterase 4 InhibitorsIBA 04/2022 - 02/2014
12	tanimilastIBA 10/2022 - 03/2015
7	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 10/2022 - 03/2015
5	Pharmaceutical PreparationsIBA 01/2021 - 02/2014
5	AnthracyclinesIBA 01/2020 - 01/2010
4	Enalapril FDA LinkGeneric 01/2020 - 12/2006
3	RoflumilastIBA 01/2021 - 01/2016
3	Budesonide (Pulmicort)FDA LinkGeneric 12/2017 - 02/2005
3	pro-brain natriuretic peptide (1-76)IBA 08/2016 - 08/2005
3	Interleukin-8 (Interleukin 8)IBA 01/2014 - 11/2007
3	Troponin IIBA 09/2010 - 06/2004
3	AldehydesIBA 05/2009 - 11/2007
3	SmokeIBA 05/2009 - 11/2007
2	Surface-Active Agents (Surfactants)IBA 01/2022 - 12/2017
2	EnzymesIBA 01/2021 - 12/2017
2	TroponinIBA 01/2020 - 01/2018
2	LipopolysaccharidesIBA 01/2019 - 10/2014
2	CytokinesIBA 01/2019 - 10/2014
2	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 09/2017 - 06/2006
2	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2016 - 03/2007
2	SteroidsIBA 01/2016 - 10/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2015 - 06/2008
2	OvalbuminIBA 03/2015 - 05/2007
2	2-butenal (crotonaldehyde)IBA 05/2009 - 07/2008
2	Formoterol Fumarate (Oxis)FDA Link 05/2007 - 02/2005
2	CholesterolIBA 12/2005 - 03/2002
2	Estrogens (Estrogen)FDA Link 10/2002 - 03/2002
1	GlucocorticoidsIBA 10/2022
1	Bronchodilator Agents (Bronchodilators)IBA 10/2022
1	EndotoxinsIBA 01/2022
1	Immunomodulating AgentsIBA 01/2021
1	microbial alkaline proteinase inhibitor (MAPI)IBA 01/2021
1	Bleomycin (Blenoxane)FDA LinkGeneric 10/2020
1	trans-crotonin (CTN)IBA 01/2020
1	Bromodeoxyuridine (BrdU)IBA 01/2020
1	Hydroxyproline (4 Hydroxyproline)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	apremilastIBA 01/2020
1	ChemokinesIBA 11/2019
1	LuciferasesIBA 01/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	Interleukin-13IBA 01/2019
1	beclomethasone 17-monopropionateIBA 01/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	Interleukin-17 (Interleukin 17)IBA 01/2019
1	ElementsIBA 01/2019
1	poractant alfa (Curosurf)FDA Link 12/2017
1	Tiotropium Bromide (Spiriva)FDA Link 09/2017
1	Methacholine Chloride (Methacholine)FDA Link 09/2017
1	Cholinergic Antagonists (Anticholinergics)IBA 09/2017
1	Losartan (Cozaar)FDA LinkGeneric 08/2016
1	Metoprolol (Toprol-XL)FDA LinkGeneric 08/2016
1	CathepsinsIBA 10/2015
1	Metalloproteases (Metalloproteinases)IBA 10/2015
1	AllergensIBA 10/2015

Therapy/Procedure

8	Therapeutics 01/2018 - 06/2006
7	Drug Therapy (Chemotherapy) 01/2020 - 06/2004
2	Topical Administration 01/2019 - 03/2015
1	Intermittent Positive-Pressure Ventilation 01/2018
1	Continuous Positive Airway Pressure 01/2017